Medicare Coverage of CBD and Hemp Products: What You Need to Know
In recent years, the landscape of product coverage under Medicare has evolved, with new pilot programs exploring the inclusion of CBD and hemp products for certain medical conditions. These products, derived from the Cannabis sativa plant, contain less than 0.3% THC, distinguishing them from marijuana in that they do not produce a psychoactive effect. Some evidence suggests these products may aid in managing symptoms like anxiety, insomnia, and muscle spasticity.
Medicare’s limited coverage of CBD and hemp comes through a pilot initiative launched by the Centers for Medicare & Medicaid Services (CMS). The Substance Access Beneficiary Engagement Incentive (BEI) allows a select group of Medicare beneficiaries to receive certain hemp-derived products under medical supervision. This program, initiated in April 2026, works by enabling CBD and hemp suppliers to provide products to accountable care organizations (ACOs) participating in the pilot. Beneficiaries can receive up to $500 annually in free products, adhering to THC limits.
Eligibility for this pilot is tightly restricted. Participants must have a physician affiliated with an ACO enrolled in the program, and the physician must determine a medical need for the products, issuing a prescription. Alternatively, patients undergoing oncology treatment under the Enhancing Oncology Model (EOM) may qualify. Furthermore, recipients must reside in regions where medical marijuana is legally recognized.
Currently, the pilot’s reach is limited, with only five ACOs having successfully registered with CMS. Yet, this trial could pave the way for broader Medicare coverage of cannabinoid-based products in the future, contingent upon federal approval and demonstrated medical efficacy.
Besides the BEI, Medicare Part D offers coverage for specific FDA-approved medications like Epidiolex, prescribed for rare epilepsy conditions, and for synthetic cannabinoids such as dronabinol and nabilone used to address chemotherapy-induced symptoms. Medicare coverage of most CBD products, including oils and creams sold over-the-counter, remains unlikely without further regulatory movement and clinical validation, as noted by industry experts like Whitney Stidom from eHealth.
As the healthcare industry continues to assess the therapeutic potential of CBD and hemp, their usage for various health conditions remains subject to ongoing research and emerging regulatory frameworks.